Pilot Project on Enhancing Support for Hidden Elderly in the Three-nil Buildings and Old Tenement Buildings: Capacity Building & Impact Evaluation

November 1, 2026 updated by: Prof. Yu, Doris Sau Fung, The University of Hong Kong

The aims of this interventional study are of two-fold. First, the study aims to develop the capacity to facilitate the collaborating NGOs to address the social determinants of aging well for 3-N seniors. The second aim of the study is to evaluate the impact of the transitional support for 3-N elders. The main question is aims to answer is:

Does the transitional support facilitate a better physical and psychological wellbeing in 3-N seniors.

Participants will be categorized into transitional-support group or non-transitional-support group based on their existing community service. They will join evaluation at four timepoints (baseline 3-, 6-, and 12-month) over the 1-year follow-up period.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The project will set up the following digital platform:

  1. Neighbor Link for Healthy Living
  2. Healthy Lifestyle Hubs without Walls
  3. Service Connect Compass Central to the concept of prompting 'aging well' through addressing the social determinants of health, the evaluation not only focuses on the direct impact on the social cohesion of the beneficiaries with their immediate community context, but also captures the indirect impact on the broader dimensions reflecting 'aging well'.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1520

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Doris Sau Fung YU, PhD
  • Phone Number: 852-3917-6319
  • Email: dyu1@hku.hk

Study Locations

  • Hong Kong
      • Hong Kong, Hong Kong
        • The University of Hong Kong
        • Contact:
          • Doris Sau Fung YU, PhD
          • Phone Number: 852-3917-6319
          • Email: dyu1@hku.hk

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Engaged in the transitional care model
  • Consent to participate in the impact evaluation
  • Able to complete the impact evaluation

Exclusion Criteria:

  • Unable or unwilling to provide informed consent
  • An acute or unstable health condition makes participation unsafe
  • Unable to complete research assessments despite reasonable support

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Intervention status

This arm covers two major service dimensions including living support and district-based caring buddy network. Participants will join evaluation at four timepoints (i.e., baseline, 3-month, 6-month, 12-month)
Behavioral: Mapped intervention based on health status

Intervention will be conducted to improve lifestyle based on their needs which include 1) Neighbor Link for Healthy Living, 2) Healthy Lifestyle Hubs without Walls and 3) Service Connect Compass.
No Intervention: No-intervention status

The corresponding no-treatment status is defined as subjects who have not received any mapped intervention for the corresponding length of time.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Edmonton Frailty Scale
Time Frame: Changes from baseline to 3 month, 6 month, 12 month post-intervention.

Overall frailty
Changes from baseline to 3 month, 6 month, 12 month post-intervention.

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Neighborhood Cohesion Inventory (HK version)
Time Frame: Changes from baseline to 3 month, 6 month, 12 month post-intervention.

Neighborhood cohesion and social engagement
Changes from baseline to 3 month, 6 month, 12 month post-intervention.
Life Space Assessment
Time Frame: Changes from baseline to 3 month, 6 month, 12 month post-intervention.

Life space mobility
Changes from baseline to 3 month, 6 month, 12 month post-intervention.
3-item UCA Loneliness Scale
Time Frame: Changes from baseline to 3 month, 6 month, 12 month post-intervention.

Loneliness
Changes from baseline to 3 month, 6 month, 12 month post-intervention.
Health-Promoting Lifestyle Profile II
Time Frame: Changes from baseline to 3 month, 6 month, 12 month post-intervention.

Lifestyle behaviors
Changes from baseline to 3 month, 6 month, 12 month post-intervention.
Social Frailty Scale-8 items (SFS-8)
Time Frame: Changes from baseline to 3 month, 6 month, 12 month post-intervention.

Social vulnerability
Changes from baseline to 3 month, 6 month, 12 month post-intervention.
Short Physical Performance Battery
Time Frame: Changes from baseline to 3 month, 6 month, 12 month post-intervention.

Measuring by (range from 0 to 12), with higher score indicating better physical performance
Changes from baseline to 3 month, 6 month, 12 month post-intervention.
Geriatric Depression Scale
Time Frame: Changes from baseline to 3 month, 6 month, 12 month post-intervention.

Psychological wellness
Changes from baseline to 3 month, 6 month, 12 month post-intervention.
Mini-nutritional Assessment
Time Frame: Changes from baseline to 3 month, 6 month, 12 month post-intervention.

Vitality
Changes from baseline to 3 month, 6 month, 12 month post-intervention.
5-minute Montreal Cognitive Assessment (MoCA)
Time Frame: Changes from baseline to 3 month, 6 month, 12 month post-intervention.

Measuring Cognitive function (range from 0 to 30), A score of 26 or over is considered to be normal.
Changes from baseline to 3 month, 6 month, 12 month post-intervention.
EuroQoL-5 Dimension-5 Level
Time Frame: Changes from baseline to 3 month, 6 month, 12 month post-intervention.

Measuring Health-related quality of life (HRQL) (range from -0.59 to 1.0), higher score indicates better quality of life
Changes from baseline to 3 month, 6 month, 12 month post-intervention.
Insomnia Severity Index (ISI)
Time Frame: Changes from baseline to 3 month, 6 month, 12 month post-intervention.

Severity of sleeping problem
Changes from baseline to 3 month, 6 month, 12 month post-intervention.
Hearing Handicap Inventory
Time Frame: Changes from baseline to 3 month, 6 month, 12 month post-intervention.

Hearing loss
Changes from baseline to 3 month, 6 month, 12 month post-intervention.
Handgrip
Time Frame: Changes from baseline to 3 month, 6 month, 12 month post-intervention.

physical wellness
Changes from baseline to 3 month, 6 month, 12 month post-intervention.
7-item Abbreviation Memory Inventory for the Chinese
Time Frame: Changes from baseline to 3 month, 6 month, 12 month post-intervention.

subjective memory complaints
Changes from baseline to 3 month, 6 month, 12 month post-intervention.
Body composition
Time Frame: Changes from baseline to 3 month, 6 month, 12 month post-intervention.

the percentages of fat and muscle in the human body
Changes from baseline to 3 month, 6 month, 12 month post-intervention.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
The University of Hong Kong

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Doris Sau Fung YU, PhD, The University of Hong Kong

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2030

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 1, 2031

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 1, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 1, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 5, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 5, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 1, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 3NIL

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings